Orphan diseases on the viewfinder
— Mitokyne, a start-up whose co-founder Johan Auwerx is a professor at EPFL, has just signed a 45 million dollars research agreement with Astellas, a Japanese pharmaceutical company. Based in Cambridge, near MIT, Mitokyne focuses on developing molecules for treating rare diseases that affect mitochondrial functions.